Literature DB >> 18337733

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer.

Rakesh K Jain1.   

Abstract

The importance of multidisciplinary translational clinical trials is obvious; however, making them work is complex and challenging. Here I present an argument for designing and implementing multidisciplinary mechanistic trials and present the lessons our team at the Massachusetts General Hospital Cancer Center has learned from two such trials in cancer patients with locally advanced rectal carcinomas and recurrent glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337733     DOI: 10.1038/nrc2346

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  73 in total

1.  Effect of wall compliance and permeability on blood-flow rate in counter-current microvessels formed from anastomosis during tumor-induced angiogenesis.

Authors:  Peng Guo; Bingmei M Fu
Journal:  J Biomech Eng       Date:  2012-04       Impact factor: 2.097

2.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 3.  The evolution of endothelial regulatory paradigms in cancer biology and vascular repair.

Authors:  Joseph W Franses; Elazer R Edelman
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

4.  Breast cancer cell-derived matrix supports vascular morphogenesis.

Authors:  Abigail C Hielscher; Connie Qiu; Sharon Gerecht
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

5.  Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Authors:  Qi Xue; Janice A Nagy; Eleanor J Manseau; Thuy L Phung; Harold F Dvorak; Laura E Benjamin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-14       Impact factor: 8.311

6.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

7.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Elena V Rosca; Farhad Vesuna; Paul T Winnard; Venu Raman; Zaver M Bhujwalla; Aleksander S Popel
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 8.  Following up tumour angiogenesis: from the basic laboratory to the clinic.

Authors:  José L Orgaz; Beatriz Martínez-Poveda; Nuria I Fernández-García; Benilde Jiménez
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

9.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

Review 10.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.